Liquidia to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary

MORRISVILLE, N.C., June 2, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced that CFO Michael Kaseta will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:00 am ET. The event runs from June 8-10, 2022, in New York City. A webcast will be available on Liquidia's investor website and archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including YUTREPIA™ inhalation powder for PAH.

News Market Reaction – LQDA

+12.08%

+12.08% Session move

In the trading session that priced this news, LQDA gained 12.08%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.

A webcast of the event will be available on the investors section of Liquidia’s website at https://liquidia.com/investors/events-and-presentations, and will be archived for 30 days following the event.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

FAQ

What is the date of Liquidia's participation in the Jefferies Healthcare Conference?

Liquidia Corporation will participate in the Jefferies Healthcare Conference on June 9, 2022.

Who will represent Liquidia Corporation at the Jefferies Healthcare Conference?

Michael Kaseta, the Chief Financial Officer of Liquidia Corporation, will represent the company.

Where is the Jefferies Healthcare Conference being held?

The Jefferies Healthcare Conference is taking place in New York City.

How can I watch the Liquidia event at the Jefferies Healthcare Conference?

A webcast of the event will be available on Liquidia's investor website.

What is the focus of Liquidia Corporation's business?

Liquidia Corporation focuses on developing treatments for pulmonary hypertension and other applications of its PRINT® Technology.